On Thursday, May 23, real-world data healthcare technology company Atropos Health announced that it had secured a $33 million Series B financing round, in light of the recent adoption of the company’s GENEVA OS™ platform, which is now being used by a variety of medical practices and researchers across the healthcare industry. The Series B financing was led by WCAS portfolio company Valtruis, as well as other investors including Cencora Ventures, McKesson Ventures, Merck Global Health Innovation Fund, and more. With this funding, Atropos is seeking to expand its offerings in value-based care, which involves the hiring of key leadership positions in the company, such as new board member Mike Spadafore, and the further development of whole-person care and value-based performance applications.
Brigham Hyde, PhD, CEO and Co-Founder of Atropos Health, expressed his excitement with the announcement in a Thursday press release, stating that the funding round was “validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data and the critical evidence needed to better inform patient care, research, and policy.” He went on to talk about how, for decades, “high-quality clinical evidence has served as the currency of value in healthcare. Atropos Health is built on investment in scaling the production of high-quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities.”
Founded in 2020 and based out of Palo Alto, California, Atropos Health has developed the “first physician consultation service powered by publication-grade real-world evidence.” The company has made a name for itself operating across 18 clinical specialties with its Rapid Analytics, On-Demand Insights, and Evidence-Based Care offerings. For more information, visit the Atropos Health website below.
See related materials: